THX Pharma and Exeltis Achieve Key Milestone for TX01 European Approval

THX Pharma, in collaboration with Exeltis, has secured a significant regulatory achievement with the European Medicines Agency's (EMA) Paediatric Committee's approval of their Paediatric Investigation Plan (PIP) for TX01. This decision advances the path toward obtaining a Paediatric Use Marketing Authorisation (PUMA) which offers up to ten years of market protection in Europe for TX01, targeting Niemann-Pick type C disease.

This milestone signifies a decisive step in meeting European paediatric regulatory standards. The PIP approval affirms the appropriateness of TX01's development strategy and paves the way for a centralised marketing authorisation across the EU, Iceland, Liechtenstein, and Norway. The PUMA framework offers regulatory and commercial benefits, enhancing TX01's position in ultra-rare disease treatments.

The partnership aims to commercialize TX01 in Europe by 2027, with subsequent plans for expansion into Latin America and selected Middle Eastern markets.